DISCOVER is a new clinical study for men who have sex with men and trans women who have sex with men. This study is to evaluate if a once-daily investigational medicine can help reduce the risk of getting HIV infection from sex (“PrEP”, or Pre-exposure Prophylaxis).
To Be Eligible:
You must be at least 18 years of age
You must be HIV negative
If you are accepted into the DISCOVER Study, you will receive study-related exams, lab tests, and study medicine at no cost.
For more information, please contact: Linden Lalley-Charezcko at 215-525-8695
PHILADELPHIA – FIGHT’s PrEP team received the prestigious Linden Award at the 19th Annual Centers for AIDS Research national meeting for their outstanding research study on PrEP (pre-exposure prophylaxis). Dr. Helen Koenig, the medical director of our PrEP Program, and the PrEP research team demonstrated that a urine test can be used to monitor adherence to Truvada™ taken as pre-exposure prophylaxis (PrEP) for prevention of HIV. This urine test has the potential to help people taking PrEP for HIV prevention and prescribing clinicians maximize the effectiveness of PrEP; a highly effective tool in ending the HIV epidemic. This work was done to address a major research gap as, currently, there is no way to reliably measure adherence to PrEP and help patients taking this medication overcome barriers to adherence.
Dr. Koenig and her team presented these results at the National Center for AIDS Research (CFAR) Symposium in Seattle, Washington where they also received award. This award, supported by funds donated to the NIH CFAR Program to advance research in HIV/AIDS, was awarded to the three investigators whose work demonstrated great significance, analytical and scientific rigor, novel/innovative methodologies, understandability to a wide scientific audience, and overall contribution to knowledge.